SLC5A2 and type 2 diabetes mellitus: Given the widely reported actions that SGLT2 inhibitors have salutary actions on cardiac function in type 2 diabetes and heart failure, which may be attributed to their ability to increase cardiac ketone metabolism [11], we were surprised by our findings in TazKD mice treated with empagliflozin.